The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society
Abstract
Objective: To update and expand the 2013 position statement of The North American Menopause Society (NAMS) on the management of the genitourinary syndrome of menopause (GSM), of which symptomatic vulvovaginal atrophy (VVA) is a component. Methods: A Panel of acknowledged experts in the field of genitourinary health reviewed the literature to evaluate new evidence on vaginal hormone therapies as well as on other management options available or in development for GSM. A search of PubMed was conducted identifying medical literature on VVA and GSM published since the 2013 position statement on the role of pharmacologic and nonpharmacologic treatments for VVA in postmenopausal women. The Panel revised and added recommendations on the basis of current evidence. The Panel's conclusions and recommendations were reviewed and approved by the NAMS Board of Trustees. Results: Genitourinary syndrome of menopause affects approximately 27% to 84% of postmenopausal women and can significantly impair health, sexual function, and quality of life. Genitourinary syndrome of menopause is likely underdiagnosed and undertreated. In most cases, symptoms can be effectively managed. A number of over-the-counter and government-approved prescription therapies available in the United States and Canada demonstrate effectiveness, depending on the severity of symptoms. These include vaginal lubricants and moisturizers, vaginal estrogens and dehydroepiandrosterone (DHEA), systemic hormone therapy, and the estrogen agonist/antagonist ospemifene. Long-term studies on the endometrial safety of vaginal estrogen, vaginal DHEA, and ospemifene are lacking. There are insufficient placebo-controlled trials of energy-based therapies, including laser, to draw conclusions on efficacy and safety or to make treatment recommendations. Conclusions: Clinicians can resolve many distressing genitourinary symptoms and improve sexual health and the quality of life of postmenopausal women by educating women about, diagnosing, and appropriately managing GSM. Choice of therapy depends on the severity of symptoms, the effectiveness and safety of treatments for the individual patient, and patient preference. Nonhormone therapies available without a prescription provide sufficient relief for most women with mild symptoms. Low-dose vaginal estrogens, vaginal DHEA, systemic estrogen therapy, and ospemifene are effective treatments for moderate to severe GSM. When low-dose vaginal estrogen or DHEA or ospemifene is administered, a progestogen is not indicated; however, endometrial safety has not been studied in clinical trials beyond 1 year. There are insufficient data at present to confirm the safety of vaginal estrogen or DHEA or ospemifene in women with breast cancer; management of GSM should consider the woman's needs and the recommendations of her oncologist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaginal microbiome of reproductive-age women
Ravel, J., Gajer, P., Abdo, Z., Schneider, G. M., Koenig, S. S. K., McCulle, S. L., Karlebach, S., Gorle, R., Russell, J., Tacket, C. O., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002611107 · Cited by 4,254
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
Raz, R., & Stamm, W. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291102 · Cited by 928
Martin, H. L., Richardson, B. A., Nyange, P. M., Lavreys, L., Hillier, S. L., Chohan, B., Mandaliya, K., Ndinya‐Achola, J. O., Bwayo, J., & Kreiss, J. (1999) · The Journal of Infectious Diseases · doi:10.1086/315127 · Cited by 891
Gosmann, C., Anahtar, M. N., Handley, S. A., Farcasanu, M., Abu-Ali, G., Bowman, B. A., Padavattan, N., Desai, C., Droit, L., Moodley, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.013 · Cited by 696
Portman, D. J., & Gass, M. L. S. (2014) · Menopause · doi:10.1097/gme.0000000000000329 · Cited by 688
Local oestrogen for vaginal atrophy in postmenopausal women
Lethaby, A., Ayeleke, R. O., & Roberts, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001500.pub3 · Cited by 601
Urinary Incontinence in Women: A Review
Lukacz, E. S., Santiago-Lastra, Y., Albo, M. E., & Brubaker, L. (2017) · JAMA · doi:10.1001/jama.2017.12137 · Cited by 555
Wiesenfeld, H. C., Hillier, S. L., Krohn, M. A., Landers, D. V., & Sweet, R. L. (2003) · Clinical Infectious Diseases · doi:10.1086/367658 · Cited by 546
Cited by
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Towards a deeper understanding of the vaginal microbiota
France, M., Alizadeh, M., Brown, S., Ma, B., & Ravel, J. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01083-2 · Cited by 382
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Metadata
- Venue
- Menopause
- Published
- 2020-09
- Volume
- 27
- Issue
- 9
- Pages
- 976-992
- ISSN
- 1072-3714 (ISSN-L)
- 1530-0374
- OpenAlex
- W4211120499
- Cited by
- 531
- References
- 156
- FWCI
- 38.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. https://app.cochat.ai/papers/10.1097/gme.0000000000001609
- The paper
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. (2020). Menopause. https://doi.org/10.1097/gme.0000000000001609
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.